• Wed news: 2025 Medicare drug price negotiations. BioAge Labs aiming at $180M IPO. Merck Keytruda colorectal cancer flop. Sanofi gets bids for consumer health unit. Novo Nordisk CEO in Senate hot seat. See more on our front page

Tick tock





These are all assumptions and the decisions haven't been made. Keep in mind that R&D has already go through a few blood baths since the Actavis/Allergan merger and it's already a pretty slim organization (in comparison).

Any one that's connected to Botox is pretty much safe and other areas depend on if Abbvie likes the Allergan design or not.

For instance, Allergan runs their own clinical trials, which is usually an outsourced operation. Not sure what Abbvie does, but if they outsource it, they have a decision to make.

You'd be surprised how many Allergan processes are being kept and how many are being combined to a happy medium.

However, Sales - I don't even think it's a department we need as a whole.

How can you be so sure? there is big overlap in different departments, for e.g. regulatory, clinical, etc. how do you think Abbvie will handle that overlap.
 




Similar threads

Replies
3
Views
2K